Axogen (AXGN) reported $225M in revenue for fiscal 2025, +20.2% year on year. That ranks #2623 by revenue among 2853 SEC filers and #277 in Healthcare. It posted a net loss of −$15.7M for the same year. Revenue has grown 31.5% a year on average since 2011 ($4.8M then). The fiscal 2025 balance sheet shows $222M in total assets, $35.5M in cash and $48.4M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenues | $225M | +20.2% | FY20252025-12-31 |
| Gross profitGrossProfit | $167M | +17.9% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$7.8M | −$4.6M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$15.7M | −$5.7M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $812,000 | −82.1% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $3.7M | +20.8% | FY20252025-12-31 |
| Total assetsAssets | $222M | +8.8% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $129M | +24.0% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $35.5M | +29.0% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $48.4M | +1.9% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $61.5M | −$19.6M | Open → |
| Q2 20262026-06-30 | $69.7M | −$1.5M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Axogen, Inc.
- Ticker
- AXGN
- Exchange
- Nasdaq
- SIC classification
- Electromedical & Electrotherapeutic Apparatus (3845)
- Fiscal year end
- 12-31
- CIK
- 0000805928
Filings
- 10-QJul 29, 2026Open filing →
- 10-QApr 28, 2026Open filing →
- 10-KFeb 24, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| TalkspaceTALK | $229M | $7.8M |
| LifevantageLFVN | $229M | $9.8M |
| Puma BiotechnologyPBYI | $228M | $31.1M |
| AxogenAXGN | $225M | −$15.7M |
| Ideaya BiosciencesIDYA | $219M | −$114M |
| Vanda PharmaceuticalsVNDA | $216M | −$221M |
| AmarinAMRN | $214M | −$38.8M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Axogen — Key figures |url=https://companiesranked.com/en/company/axogen |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Axogen — Key figures. CompaniesRanked. https://companiesranked.com/en/company/axogenBibTeX
@misc{companiesranked-en-company-axogen-2026,
author = {{CompaniesRanked}},
title = {{Axogen — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/axogen}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0000805928-26-000031 · February 24, 2026
{{cite web |title=Axogen — Key figures — 10-K (0000805928-26-000031) |url=https://www.sec.gov/Archives/edgar/data/805928/000080592826000031/axgn-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-24}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.